192. Cockayne syndrome Clinical trials / Disease details


Clinical trials : 4 Drugs : 7 - (DrugBank : 3) / Drug target gene : 1 - Drug target pathways : 51

  
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR1900026719
2019-11-012019-10-19Clinical study for combined application of vitamin C and quercetin in the treatment of Cockayne's syndromeClinical study for combined application of vitamin C and quercetin in the treatment of Cockayne's syndrome Cockayne's syndrometest group:Vitamin C and Quercetin;The First Medical Center of PLA General HospitalNULLPending613Bothtest group:20;China
2NCT03016715
(ClinicalTrials.gov)
May 20169/1/2017Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) StudyA Prospective, Double-Blind, Cross-Over, Pilot Study to Assess Safety and Efficacy of Topical Sirolimus 2% in the Treatment of Plantar Blistering in Patients With Epidermolysis Bullous Simplex (EBS)Epidermolysis Bullosa Simplex;Epidermolysis Bullosa Simplex Kobner;Weber-Cockayne SyndromeDrug: Sirolimus 2%;Drug: VehiclePremier Specialists, AustraliaNULLRecruiting5 YearsN/AAll8Phase 2Australia
3NCT02960997
(ClinicalTrials.gov)
May 201615/6/2016Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) StudyA Prospective, Double-Blind, Cross-Over, Pilot Study to Assess Safety and Efficacy of Topical Sirolimus 2% in the Treatment of Plantar Blistering in Patients With Epidermolysis Bullous Simplex (EBS)Epidermolysis Bullosa Simplex;Epidermolysis Bullosa Simplex Kobner;Weber-Cockayne SyndromeDrug: Sirolimus, 2%;Drug: VehicleStanford UniversityNULLActive, not recruiting4 YearsN/AAll8Phase 2United States
4NCT01142154
(ClinicalTrials.gov)
June 201020/5/2010Pharmacokinetics and Safety Study of Single and Multiple Oral Doses Prodarsan™ in Patients With Cockayne SyndromeA Phase I/II Crossover Study To Evaluate and Compare the Pharmacokinetics of a Single IV Dose of D-Mannitol (Osmitrol®10%) to Single and Multiple, Escalating Doses of Liquid, Oral Prodarsan™ in Patients With Cockayne SyndromeCockayne SyndromeDrug: ProdarsanDNage B.V.NULLCompleted2 Years10 YearsBoth5Phase 1/Phase 2United States